Tag: CH:ROG
-
Roche’s Tecentriq shows further good survival rates as cancer treatment
[ad_1] Roche Holding AG said Sunday that its tecentriq immunotherapy drug showed further positive results in an advanced study, demonstrating significant improvement in recurrence-free survival in patients. Tecentriq plus Avastin reduced the risk of recurrence of disease by 28% in patients with hepatocellular carcinoma at high risk of recurrence after liver resection or ablation with…